Xilio Therapeutics (XLO) News Today $0.84 -0.06 (-7.04%) Closing price 04:00 PM EasternExtended Trading$0.84 +0.01 (+1.20%) As of 05:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock XLO Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial ResultsMay 8, 2025 | finanznachrichten.deXilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial ResultsMay 8, 2025 | finance.yahoo.comXilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comXilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 2, 2025 | globenewswire.comXilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual MeetingApril 23, 2025 | globenewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 4, 2025 | globenewswire.comXilio Therapeutics reports Q4 EPS (20c) vs (64c) last yearMarch 11, 2025 | markets.businessinsider.comXilio Therapeutics files $250M mixed securities shelfMarch 11, 2025 | markets.businessinsider.comXilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial ResultsMarch 11, 2025 | globenewswire.comXilio Therapeutics to Present at TD Cowen 45th Annual Health Care ConferenceFebruary 24, 2025 | globenewswire.comXilio Therapeutics, Inc.: Xilio Therapeutics Announces Multiple Masked T Cell Engager ProgramsFebruary 12, 2025 | finanznachrichten.deXilio Therapeutics Shares Surge Premarket on AbbVie DealFebruary 12, 2025 | marketwatch.comAbbVie, Xilio Hook upFebruary 12, 2025 | baystreet.caXilio Therapeutics Announces Multiple Masked T Cell Engager ProgramsFebruary 12, 2025 | globenewswire.comAbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated ImmunotherapiesFebruary 12, 2025 | globenewswire.comAbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated ImmunotherapiesFebruary 12, 2025 | prnewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 3, 2025 | globenewswire.comXilio reports results from ongoing Phase 2 clinical trial of vilastobartJanuary 23, 2025 | markets.businessinsider.comXilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal CancerJanuary 21, 2025 | globenewswire.comXilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)January 17, 2025 | globenewswire.comXilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)January 10, 2025 | globenewswire.comXilio Therapeutics to present initial Phase 2 data for XTX101 at ASCO GIDecember 20, 2024 | markets.businessinsider.comXilio Therapeutics Secures $25M Investment from GileadDecember 20, 2024 | markets.businessinsider.comXilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GIDecember 19, 2024 | globenewswire.comXilio Therapeutics appoints Caroline Hensley as CLODecember 17, 2024 | markets.businessinsider.comXilio Therapeutics Appoints Caroline Hensley as Chief Legal OfficerDecember 16, 2024 | globenewswire.comHere's Why We're Not Too Worried About Xilio Therapeutics' (NASDAQ:XLO) Cash Burn SituationDecember 6, 2024 | uk.finance.yahoo.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 3, 2024 | globenewswire.comPromising Pipeline and Financial Stability Drive Buy Rating for Xilio TherapeuticsNovember 9, 2024 | markets.businessinsider.comXilio Therapeutics Reports Q3 2024 Progress and FinancialsNovember 9, 2024 | markets.businessinsider.comXilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial ResultsNovember 8, 2024 | finance.yahoo.comXilio Therapeutics Advances Cancer Drug and Financial OutlookNovember 8, 2024 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on Xilio Therapeutics (XLO)November 8, 2024 | markets.businessinsider.comXilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024Â Financial ResultsNovember 7, 2024 | globenewswire.comXilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid TumorsNovember 7, 2024 | globenewswire.comXilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual MeetingOctober 30, 2024 | globenewswire.comXilio Therapeutics (NASDAQ:XLO) Stock Quotes, Forecast and News SummaryOctober 17, 2024 | benzinga.comXilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual MeetingOctober 4, 2024 | globenewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2024 | finance.yahoo.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2024 | globenewswire.comXilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare ConferenceAugust 28, 2024 | globenewswire.comXLO Stock Earnings: Xilio Therapeutics Misses EPS for Q2 2024August 8, 2024 | investorplace.comXilio Therapeutics, Inc.: Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial ResultsAugust 8, 2024 | finanznachrichten.deXilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial ResultsAugust 8, 2024 | globenewswire.comXilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D.June 13, 2024 | globenewswire.comXLO Stock Earnings: Xilio Therapeutics Misses EPS for Q1 2024May 14, 2024 | investorplace.comXilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial ResultsMay 14, 2024 | globenewswire.comXilio Therapeutics (XLO) Price Target Increased by 17.86% to 5.61April 17, 2024 | msn.com3 Biotech Stocks to Invest In Right Now for Long-Term GainsApril 12, 2024 | stocknews.comGilead Sciences, Inc. Buys 485,250 Shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) StockApril 4, 2024 | insidertrades.com Get Xilio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for XLO and its competitors with MarketBeat's FREE daily newsletter. Email Address XLO Media Mentions By Week XLO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. XLO News Sentiment▼0.000.66▲Average Medical News Sentiment XLO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. XLO Articles This Week▼00▲XLO Articles Average Week Get Xilio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for XLO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PBYI News Today KRRO News Today LFVN News Today SLS News Today FTLF News Today NKTX News Today CYBN News Today TNGX News Today EPRX News Today ACRS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:XLO) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xilio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xilio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy XLO Stock Free XLO Stock Alerts